Literature DB >> 6440982

Radiographic evaluation of erosion in rheumatoid arthritis: double blind study of auranofin vs placebo.

J P Gofton, W M O'Brien, J N Hurley, B J Scheffler.   

Abstract

PA radiographs of hands and wrists from a randomized 6 month study of auranofin (AF) vs placebo followed by 6 months of open AF were scored for progression of erosive disease by 2 independent readers. The readers were blinded both to treatment and sequence (month 0 vs month 12) of the films. The results of our study demonstrate a reduction in the advancement of erosive disease during AF therapy compared to placebo.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6440982

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  In rheumatoid arthritis is compliance in physicians more of a problem than compliance in patients?

Authors:  R J Rooney; W W Buchanan
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

2.  Effects of aurothioglucose and auranofin on radiographic progression in rheumatoid arthritis.

Authors:  P L Van Riel; A Larsen; L B Van de Putte; F W Gribnau
Journal:  Clin Rheumatol       Date:  1986-09       Impact factor: 2.980

3.  A three year follow up of patients allocated to placebo, or oral or injectable gold therapy for rheumatoid arthritis.

Authors:  H A Capell; D Lewis; J Carey
Journal:  Ann Rheum Dis       Date:  1986-09       Impact factor: 19.103

4.  Radiological evaluation of erosions: a quantitative method for assessing long-term remittive therapy in rheumatoid arthritis.

Authors:  W M O'Brien
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

5.  The effects of auranofin and parenteral gold in the treatment of rheumatoid arthritis: an X-ray analysis.

Authors:  A Larsen; J Horton; C Howland
Journal:  Clin Rheumatol       Date:  1984-03       Impact factor: 2.980

6.  Radiological progression in rheumatoid arthritis: how many patients are required in a treatment trial to test disease modification?

Authors:  J T Sharp; F Wolfe; M Corbett; H Isomaki; D M Mitchell; D E Furst; J Sibley; M Shipley
Journal:  Ann Rheum Dis       Date:  1993-05       Impact factor: 19.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.